Registration is open! Oct 3–4 @ PA Convention Center, Philadelphia. The 2nd Annual Advancing Precision Medicine Conference: "Advances in Precision Oncology: From Genomics to Targeted Therapies" is free and in person. Ft. Nobel Laureate Dr. Kaelin. https://bit.ly/48odQpH

At 3600 Civic Center Blvd, E. John Wherry, PhD welcomed Good Morning Philadelphia to Penn Medicine's new hub for hundreds of researchers in immune health, infectious disease, population health data sciences, and others engaged in cross-disciplinary collaboration. https://bit.ly/4mmwd1w

⏱️ Every minute in the United States, someone needs a blood transfusion because of their period. Penn’s Dr. Kathleen O’Neill is developing an mRNA therapy to treat abnormal uterine bleeding and uncover its causes—a potential breakthrough for menstrual health and #mRNA technology. bit.ly/4n8rGkB

Last week, Penn Medicine leaders cut the ribbon on a new home for #immunology research. The eight-story "overbuild" at 3600 Civic Center Blvd will house I3H, #ImmuneHealth, @penncoltoncenter.bsky.social, and related areas to foster interdisciplinary collaboration. ▶️ Watch: youtu.be/Ryv2AxPtb_E?...

Healthy blood cells can live without ARHGAP45—but acute myeloid leukemia cells can’t. 🩸 Junwei Shi, PhD (Associate Professor of Cancer Biology) and team show a CAR T + CDC42 inhibition strategy could target AML with minimal side effects. bit.ly/45OyXQu

Congratulations to @joelbabdor.bsky.social (@PennSysPharmATT/ @i3h-upenn.bsky.social), recipient of a 2025 @lupusresearch.bsky.social Empowering Lupus Research Career Development Award! tinyurl.com/yc3x6n2m

What's the difference between Trm and exhausted CD8 T cells? Simone Park's new work dissects this important question. These cell types are often confused, but are ontologically and mechanistically distinct with implications for immunotherapy responses. www.biorxiv.org/content/10.1...

The RVCL Research Center at @upenn.edu, led by Jonathan Miner, MD, PhD, is pushing the boundaries of immune health with new discoveries about TREX1—a gene linked to RVCL, as well as cancer, autoimmune diseases, and aging. Discover how visionary philanthropy is fueling research: bit.ly/4frCSWI

A new study shows Cul5 helps prevent overproduction of certain blood cells by keeping key signals in check. A common drug may help restore that balance. Read the full JCI article ft. Paula Oliver (@pennpathlabmed.bsky.social) and colleagues: www.jci.org/articles/vie...

Dispatch Bio—a new startup aiming to create a universal #immunotherapy approach for all cancers—officially launched this week. Among its scientific co-founders is CAR T cell pioneer Carl June, MD—and the @upenn.edu is an early investor.

Mitochondrial complex IV remodeling plays a key role in how macrophages adapt to their surroundings—findings with major implications for #immunotherapy. Check out the newest study from Penn Medicine (@pennmedicine.bsky.social) researchers published in Immunity (@cp-immunity.bsky.social).

Join @i3h-upenn.bsky.social on 6/18 for their Year in Review Symposium ft'ing keynote speaker Ruslan Medzhitov (@yaleschoolofmed.bsky.social). Learn more➡️ tinyurl.com/298vrkbr

Stay connected with us beyond Bluesky 👋 Follow the Institute for Immunology and Immune Health (I3H) on LinkedIn for deep dives into Penn’s groundbreaking #immunology research and the future of #ImmuneHealth. www.linkedin.com/company/penn...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get this powerful therapy to more people https://go.nature.com/45w5A5w

I'm very excited to share that @upenn.edu @i3h-upenn.bsky.social #MSTP and Hill Lab student Julia Chini will be defending her #PhD thesis on #CD9, #obesity, and #macrophages on Wednesday, June 11th at 1PM in BRB Auditorium. Please join us as we support and celebrate Julia!

Carl June and Bruce Levine of @upenn.edu—along with Isabelle Rivière, and Michel Sadelain (formerly of @mskcancercenter.bsky.social)— have been jointly awarded the 2025 Richard N. Merkin Prize in Biomedical Technology for developing chimeric antigen receptor (CAR) T-cell therapy. bit.ly/43G8kec

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients with B-cell lymphoma who had exhausted other treatment options ft. @carlhjune (@pennpathlabmed.bsky.social) & Jakub Svoboda (@penncancer.bsky.social) @i3h-upenn.bsky.social tinyurl.com/3ejw9334

Deputy Director of Innovation and Technology (I3H) and Associate Professor of Genetics (Perelman School of Medicine), Dr. Golnaz Vahedi (@vahedilab.bsky.social), discussed "Chromatin topology at paralogous transcription factors" during a recent "Global Immunotalks" seminar. Check it out!

Our partners at the @penncoltoncenter.bsky.social are doing innovative work in #autoimmunity — bridging the gap between groundbreaking research and real-world clinical applications. Give them a follow and check out their symposium recap to discover how they’re shaping the future of #ImmuneHealth.

Congratulations to I3H members, Susan Weiss, (Vice Chair and Professor, Dept. of Microbiology), Dennis Discher (Robert D. Bent Professor, Dept. of Chemical & Biomolecular Engineering), and our other esteemed @upenn.edu colleagues on being elected to the American Academy of Arts & Sciences. 👏

Genetic screening may have unlocked a path for treating the severe inflammation associated with many immune diseases by regulating one protein’s role in helping another protein control cell acidity, according to recent research published in Cell by the @minerlab.bsky.social. 🔗 tinyurl.com/ycxf6stn

A major breakthrough from @pennmedicine.bsky.social: @davidfajgenbaum.bsky.social and team have identified a new subtype—Oligocentric Castleman Disease (OligoCD)—marking the first Castleman discovery in 45 years. This could transform diagnosis and care for thousands. Published in Blood Advances.

New in @naturecancer.bsky.social: Solid tumors can trigger CAR T cell “friendly fire” via tiny vesicles. In this study, @upenn.edu scientists engineered CAR T cells to resist this, boosting tumor-fighting power in female mice—a promising advance for solid tumor immunotherapy.

Breakthrough at @pennmedicine.bsky.social: A next-gen “armored” CAR T cell therapy shrank lymphoma in 81% of patients who had exhausted all other options. Over half went into complete remission. Published in @nejm.org ft. Jakub Svoboda, MD and Carl H. June, MD. @penncancer.bsky.social bit.ly/42R6J6a

Congrats @davidfajgenbaum.bsky.social on being named to the TIME100 Health 2025 list! After being diagnosed with Castleman disease, he found an existing drug that saved his life. Now he’s using AI to repurpose FDA-approved drugs—offering hope to others with hard-to-treat conditions. bit.ly/4kdkgdX

Congratulations to @ejohnwherry.bsky.social and Penn colleagues, Katalin Karikó, Virginia Lee (@pennpathlabmed.bsky.social) and Mark Devlin on being elected as members of the @nasonline.org—one of the highest honors a scientist can receive!